Tuberculosis: An Overview of the Immunogenic Response, Disease Progression, and Medicinal Chemistry Efforts in the Last Decade toward the Development of Potential Drugs for Extensively Drug-Resistant Tuberculosis Strains.
Akanksha SharmaMaria De RosaNeha SinglaGurpal SinghRavi Pratap BarnwalAnkur PandeyPublished in: Journal of medicinal chemistry (2021)
Tuberculosis (TB) is a slow growing, potentially debilitating disease that has plagued humanity for centuries and has claimed numerous lives across the globe. Concerted efforts by researchers have culminated in the development of various strategies to combat this malady. This review aims to raise awareness of the rapidly increasing incidences of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis, highlighting the significant modifications that were introduced in the TB treatment regimen over the past decade. A description of the role of pathogen-host immune mechanisms together with strategies for prevention of the disease is discussed. The struggle to develop novel drug therapies has continued in an effort to reduce the treatment duration, improve patient compliance and outcomes, and circumvent TB resistance mechanisms. Herein, we give an overview of the extensive medicinal chemistry efforts made during the past decade toward the discovery of new chemotypes, which are potentially active against TB-resistant strains.
Keyphrases
- multidrug resistant
- drug resistant
- mycobacterium tuberculosis
- acinetobacter baumannii
- gram negative
- pulmonary tuberculosis
- klebsiella pneumoniae
- hiv aids
- escherichia coli
- small molecule
- quality improvement
- adverse drug
- emergency department
- case report
- high throughput
- pseudomonas aeruginosa
- metabolic syndrome
- replacement therapy
- drug discovery
- type diabetes
- drug induced
- adipose tissue
- smoking cessation
- climate change
- human health